EUCTR2021-006276-16-IE进行中（未招募）1 期
PaTcH Trial: A phase 2 study to explore primary and emergingresistance mechanisms in patients with metastatic refractory pancreatic cancer treated with trametinib and hydroxychloroquine. - PaTcH Trial.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients must have pathologically confirmed advanced metastatic pancreatic adenocarcinoma or poorly differentiated pancreatic adenocarcinoma that is amenable to tumour biopsy.
- •2. Patients have received at least one line of systemic therapy for metastatic disease and not be amenable to surgical resection.
- •3. Patients must have measurable disease by RECIST 1.1 criteria.
- •4. Age =18 years.
- •5. ECOG performance status = 1
- •6. Patients must have normal organ and marrow function as defined below:
- •a. Serum creatinine = 1.5 x ULN.
- •b. Adequate hepatic function defined by:
- •o total bilirubin level = 1.5 × ULN,
- •o an AST, level = 2.5 × ULN, and an ALT level = 2.5 × ULN (or, for subjects with documented metastatic disease to the liver, AST and ALT levels = 5 × ULN)
- •c. Hematological eligibility parameters:
- •o Absolute Neutrophil count = 1.5 x 10^9/L
- •o Platelet count =100 x10^9/L
- •o Hemoglobin = 9 g/dL
- •7. Ability of subject to understand and the willingness to sign a written informed consent document.
- •8. Women of child-bearing potential or sexually active males must agree to use highly effective contraceptive measures. This applies from starting treatment until at least 16 weeks after the last study drug administration. The investigator or a designated associate is required to advise the patient how to achieve an adequate birth control. Highly effective contraception is defined in the study as methods that achieve a failure rate of less than 1% per year when used
- •consistently and correctly. Such methods include:
- •I. Combined (oestrogen and progestogen containing) hormonal contraception
- •associated with inhibition of ovulation (oral, intravaginal, transdermal).
- •II. Progestogen-only hormonal contraception associated with inhibition of ovulation
- •(oral, injectable and implantable).
- •III. Intrauterine device (IUD).
- •IV. Intrauterine hormone-releasing system (IUS).
- •V. Bilateral tubal occlusion.
- •VI. Successfully vasectomised partner.
- •VII. Sexual abstinence.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 11
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 11
排除标准
- •1. Persisting toxicity related to prior therapy (CTCAE Grade > 1); however alopecia, sensory neuropathy Grade = 2, or other Grade =2 AEs not constituting a safety risk based on
- •investigator's judgment are acceptable.
- •2. Prior treatment with a MEK inhibitor.
- •3. Known history of testing positive for Human Immunodeficiency Virus (HIV) or known acquired
- •immunodeficiency syndrome.
- •4. Any significant disease that, in the opinion of the investigator, may impair the patient’s tolerance of study treatment.
- •5. Patients who are receiving any other investigational agents within 28 days before start of study treatment.
- •6. Prior organ transplantation including allogenic stem-cell transplantation.
- •7. Patients with known central nervous system metastases.
- •8. Active uncontrolled infection, requiring systemic therapy.
- •9. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (= New York Heart Association Classification Class II), or serious
- •cardiac arrhythmia requiring medication.
- •10. Severe left ventricular dysfunction as defined by ejection fraction < 45%.
- •11. Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behaviour; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- •12. Known maculopathy of the eye.
- •13. Known history or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes).
- •14. Screening corrected QT interval by Fridericia (QTcF) > 500 msec.
- •15. Pregnant women and breastfeeding mothers are excluded due to unknown impact on embryos or infants.
- •16. Known prior severe hypersensitivity to investigational products or any component in its formulation.
- •17. Concurrent use of medicines known to induce retinal toxicity (e.g. tamoxifen) or QT interval prolonging agents.
- •18. Known congenital or documented acquired QT prolongation.
- •19. Uncorrected hypokalemia and/or hypomagnesemia.
研究者
相似试验
招募中
1 期
PaTcH Trial: A phase 2 study to explore primary and emerging resistance mechanisms in patients with metastatic refractory Pancreatic cancer treated with Trametinib and Hydrochloroquine.Metastatic refractory Pancreatic CancerMedDRA version: 21.1Level: LLTClassification code: 10033605Term: Pancreatic cancer metastatic Class: 10029104CTIS2024-513429-21-00Cancer Trials Ireland22
进行中（未招募）
2 期
A clinical trial of neoadjuvant taxane chemotherapy for women with locally advanced breast cancerocally advanced breast cancerLocally advanced breast cancerCancer - BreastACTRN12606000305527The Cancer Council Victoria40
进行中（未招募）
1 期
A RANDOMIZED PHASE 2 CLINICAL TRIAL TO EVALUATE THE ACTIVITY OF ATRA IN COMBINATION WITH ANASTROZOLE IN PRE-OPERATIVE PHASE OF OPERABLE HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCEREBC ATRA TRIAPatients with newly, untreated, resectable HR+/HER2- eBCs, suitable for pre-operative therapy with anastrozoleMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001856-36-ITIRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI112
尚未招募
2 期
Gene Xpert XDR-TB Kit EvaluatioCTRI/2019/07/020139Foundation for Innovative New Diagnostics India
进行中（未招募）
1 期
PHASE I-II CLINICAL TRIAL FOR THE EVALUATION OF THE ROLE OF BRENTUXIMAB VEDOTIN PLUS ETOPOSIDE, SOLUMODERIN, HIGH DOSE ARA-C AND CIS-PLATIN IN THE TRANSPLANT AND POST-TRANSPLANT MANAGEMENT FOR PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMAEUCTR2014-000835-17-ESGELTAMO (Grupo Cooperativo Español de Linfoma/Trasplante Autólogo de Médula Ósea)66